Cell Proliferation Assays

Info in Brief

Free choice setup

The free choice setup, allows the client to test any number of compounds against any number of cell lines. Screening can be performed in single concentration mode for high-throughput projects or IC50 mode (8 concentrations in duplicates).

InfoSheet: Cell Proliferation Assay

ProLiFiler plus Bioinformatics Analysis

Testing is performed on a panel of 140 human tumor cell lines with IC50 value determination (8 concentrations, duplicates).

Timelines: We are performing continuous screening and start over every 6 weeks. 

Bioinformatics analysis: We collaborate with 4HF Biotech GmbH, who specializes in data mining with a focus on anti-cancer drug discovery and will support our ProLiFiler, a cell panel screening service, for meaningful interpretation of results. 4HF Biotec has compiled a database including proprietary and literature data, including 1,800 preclinical samples and more than 700 reference drugs.

The bioinformatics analysis can identify:

1. The mechanism of action of your compound
2. Suitable biomarkers that correlate with the efficacy of your drug

InfoSheet ProLiFiler and bioinformatics analysis

Drug Combination Testing

ProQinase tests drug combination with either one-sided or two-sided approaches in either low or high-throughput setups. Drug Combination Testing is available for both, cell proliferation assay on a custom panel of cell lines or the ProLiFiler comprising testing of 120 cell lines.

Poster: Analysis of the combinatorial anti-proliferative effect of panRAF inhibitor AZ-628 and MEK1 inhibitor Selumetinib on a large panel of tumor cell lines.

Info_Sheet: Drug Combination Testing

Cpd Exposure

72 h

Readout

CellTiter-Glo® Luminescent

Testing Formats

IC50 (8 semi-log dilutions in duplicate)

Cpd Submission

Solved or as pre-weighed powder

Reference Cpd

included

Report

Comprehensive evaluation of data including raw data for own analysis
Sample report will be provided upon request

Guidelines for Cpd Submission

EXCEL-FILE

Reference compounds tested in the Cell Proliferation Assay

Tozasertib (MK-0457, VX-680), GSK2981278, Doxorubicin (Doxil, Adriablastin), Paclitaxel (Taxol A, Abraxane), Bortezomib (Velcade), Staurosporine, PHA665752, Sunitinib (Sutent), Everolimus (Afinitor), VE-821, Cisplatin (platamin, neoplatin), Selumetinib (AZD6244, ARRY-142886), AZ628; UNC-2025, R-428, Actinomycin D (Dactinomycin), Mertansine (DM1, Maytansinoid), Monomethylauristatin E (MMAE; SGD-1010), Trametinib (GSK1120212), Crizotinib (Xalkori), A1210477, S68345, Navitoclax (ABT-263), Panobinostat (LBH589,  NVP-LBH589)